Skip to main content
Premium Trial:

Request an Annual Quote

Singulex Will Use $900K NCI Contract to Develop Response Assays With Sigma-Aldrich, WashU

NEW YORK (GenomeWeb News) — Singulex today said it will receive a $900,000 Phase I/II Fast Track Small Business Innovation Research contract from the National Cancer Institute to create biomarker assays to predict patient response and efficacy of cancer drugs in development.
 
The company has also penned a collaboration with Washington University’s School of Medicine to “increase the clinical utility” of validated and newly discovered biomarkers in human disease.
 
As part of the SBIR contract, Singulex will collaborate with Wash U and St. Louis-based Sigma-Aldrich. The company will use Wash U-held biological samples and optimized reagents from Sigma-Aldrich to develop assays to detect expression-level changes for a panel of proteins associated with cancer growth.
 
“The goal of these assays is to measure the efficacy of potential anticancer drugs earlier in the developmental process and provide insight to patients' response to new candidate therapeutic agents,” Singulex, also based in St. Louis, said in the statement.
 
"Biomarkers indicative of disease states are increasingly crucial to translating basic science breakthroughs into better patient outcomes," Singulex CEO Philippe Goix said in the statement. He said that the company's flagship Erenna biomarker-detection platform can measure small changes of biomarkers "from healthy to disease states to provide answers not only about disease progression but also therapeutic efficacy of drugs in development."
 
As part of the first alliance, scientists at Wash U’s School of Medicine will gain access to the Erenna technology to help develop assays for validated and putative biomarkers in diseases such as breast cancer, Alzheimer's disease, diabetes, and stroke.
 
An Erenna system has been installed in the proteomics core facility at Washington University's Siteman Cancer Center.
 
"Together with Singulex, we want to determine whether the Erenna system can assess the effectiveness of novel anti-cancer drugs early in their development and predict patients' responses to these therapies,” Samuel Stanley, vice chancellor of research at Wash U, said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more